Mergers and Acquisitions LIFE SCIENCES

With decades of experience advising on all aspects of mergers and acquisitions, WilmerHale is the go-to firm for life sciences companies.


Mergers and acquisitions are prevalent in the life sciences industry because of the consolidating nature of the industry, and because of the importance of acquisitions as an exit strategy for biotechnology investors. We have significant experience in representing public and private clients in all types of M&A transactions, including stock-for-stock mergers, cash mergers, tender offers, acquisitions and dispositions of divisions, product lines and spin-offs. We also have particular knowledge and experience with milestone-based life sciences deals.

When it comes to mergers and acquisitions, our clients benefit from the broad range of relevant skills—securities, patent, regulatory, tax and antitrust/competition—that our attorneys bring to bear. In 2016, we advised clients throughout the United States and Europe on more than 75 M&A transactions, providing guidance across industries in areas including corporate, securities, antitrust and tax. Since 2006, we have participated in more than 1,000 mergers and acquisitions with a total value in excess of $400 billion, ranging from sales of VC-backed companies to multibillion-dollar global mergers.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Experience

Representative M&A transactions include:

  • Aciex Therapeutics' acquisition by Nicox for $120 million (including earnout payments);
  • BioVex's acquisition by Amgen for $1 billion (including milestone payments);
  • cCam Biotherapeutics' acquisition by Merck for $510 million (including contingent payments);
  • Durata Therapeutics' acquisition by Actavis for $760 million;
  • Enobia Pharma's acquisition by Alexion Pharmaceuticals for $1.1 billion (including milestone payments);
  • ISTA Pharmaceuticals' acquisition by Bausch + Lomb for $500 million;
  • Palomar Medical Technologies' acquisition by Cynosure for $294 million;
  • PerkinElmer's acquisition of Caliper Life Sciences for $600 million;
  • Stromedix's acquisition by Biogen Idec for $562.5 million (including milestone payments);
  • The Medicines Company's acquisition of Incline Therapeutics for $390 million (including milestone payments) and Rempex Pharmaceuticals for $474 million (including milestone payments), and in the sale of its global portfolio of hemostasis products to Mallinckrodt for $410 million;
  • Thermo Fisher Scientific's acquisition of One Lambda for $925 million and Phadia for €2.47 billion, and its sale of its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare for $1.06 billion; 
  • TEI Biosciences' acquisition by Integra Life Sciences for $312 million; and 
  • Vtesse's acquisition by Sucampo Pharmaceuticals for $200 million (not including contingent payments).

Publications & News

View

January 26, 2018

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Karyopharm Therapeutics Inc. announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions.

January 3, 2018

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

Viamet Pharmaceuticals (NC), Inc. today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161.

December 22, 2017

WilmerHale Advises Centurion in Acquisition by Medline

On December 7, 2017, Medline completed its acquisition of Centurion Medical Products, a Michigan-based medical supplies manufacturer. The company will continue to operate as a subsidiary of Medline.

December 5, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

June 7, 2017

Selected 2017 Life Sciences Transactions

Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.

May 26, 2017

WilmerHale Lawyers and Practices Recognized in 2017 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2017 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 86 WilmerHale lawyers as leaders in their respective fields.

May 17, 2017

WilmerHale Ranks Among Top Three Life Sciences Law Firms for Second Consecutive Year

The index—launched last year by Lake Whillans and Breaking Media (publisher of MedCity News and Above the Law)—identifies which law firms are the most active and relevant for life sciences companies.

April 28, 2017

2017 Corporate Reports

WilmerHale's annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

March 21, 2017

WilmerHale Recognized for Outstanding International Lawyers and Practices in Chambers Global 2017

Chambers Global has named 27 WilmerHale lawyers among "The World's Leading Lawyers for Business" in its 2017 edition.